Opioid Rotation. Dr Bruno Gagnon, M.D., M.Sc.
|
|
- Toby Lucas
- 5 years ago
- Views:
Transcription
1 Opioid Rotation Dr Bruno Gagnon, M.D., M.Sc. Associate Professor Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval Consultant in Palliative Medicine CHU de Québec-Université Laval, L Hôtel-Dieu de Québec
2 Disclosure of Financial Support This program has not received financial support This program has not received in-kind support No conflict of interest
3 Faculty/Presenter Disclosure Faculty: Faculty of Medicine, Laval University Relationships with financial sponsors: None
4 As a result of attending this presentation, the learner will become competent with the rationale for the practice of rotating narcotics when, how and why one would choose to alter treatment in this manner. be able to discuss the most common pitfalls in rotating narcotics.
5 Plan Definition Brief explanation of scientific basis Indications and process 3 clinical vignettes Comments on methadone Take home tips
6 Level of evidences Animal studies Retrospective cohort studies Experts opinions
7 Opioid rotation (switching) Process of substituting on opioid to another Objectives: Improve pain control Reduce intensity of adverse effects Mercadante S., Cancer, 1999
8 Genetic variabilities in opioid receptors Tolerance development to analgesic and toxic effects time; analgesic toxic effects morphine dose analgesic < toxic between different opioids Analgesic/toxic is influenced by: Exposure time Illness progress Incomplete cross tolerance Opioid switching or rotation
9 In conclusion: opioids differ in Effectiveness Ability to induce toxicity
10 Fractional Receptor Occupancy Efficacy Minimum % of receptors occupancy necessary Efficacy is inversely proportional to receptor occupancy Receptor Occupancy June 24th, 2012
11 Receptor Occupancy and Efficacy % Receptor occupancy 80 % Fentanyl (F) High efficacy/low occupancy requirement Morphine (M) Low efficacy/high occupancy requirement Efficacy June 24th, 2012
12 Trials and errors
13 Indications and Process Clinical Vignette 1 Clinical Vignette 2 Clinical Vignette 3
14 Clinical Vignette 1 You are seen M. John in outpatient clinic 62 year s old man Diagnosed 6 months previously with NSCLC RLL Chest wall invasion and liver metastases No comorbidities Chimotx as a palliative modality
15 Clinical Vignette 1 Initially R lateral chest wall pain 7/10 (7 th - 8 th ribs) Mildly burning BTP: electric shocks like Initiation and titration up of morphine Gabapentin
16 Clinical Vignette 1 No more chemotherapy Diffuse R chest wall pain 9/10 From sternum to back Burning pain 3/10 in both arms and legs No other complaints
17 Clinical Vignette 1 Gabapentin 75 mg PO BID Morphine LA 120 mg PO BID Since 4 days, 5-6 BTA of 25 mg of IR Morphine/day
18 Clinical Vignette 1 What is the underlying pathophysiological process responsible for the sudden worsening of the pain syndrome? 1. Opioid neurotoxicity 2. Opioid tolerance 3. Specific opioid low responsiveness 4. Hyperalgesia 5. Progression of disease
19 Question What is the underlying pathophysiological process responsible for the sudden worsening of the pain syndrome? 1. Opioid neurotoxicity 2. Opioid tolerance 3. Specific opioid low responsiveness 4. Hyperalgesia 5. Progression of disease
20 Hyperalgesia: Rotation from Morphine to Hydromorphone Hydromorphone % of Response 80 % Ratio 1 Ratio 2 Morphine Hyperalgesia Ratio 1 < Ratio 2 Dosage 20 June 24th, 2012
21 Decision to switch to hydromorphone What is the conversion ratio of Morphine to hydromorphone? 1. 2:1 2. 3:2 3. 5: :1
22 Decision to switch to hydromorphone What is the conversion ratio of Morphine to hydromorphone? 1. 2:1 2. 3:2 3. 5: :1
23 How do we proceed? Many ways to skin a cat! Morphine: 240 (325 BTA) mg orally/day = 48 (65) mg of hydromorphone orally/day Discontinue morphine Start HM at 36 mg orally/day ( %) (6 mg q 4 hrs) BTA: 4 mg q 1 hr % of is a clinical judgement issue Pitfall: too much or not enough
24 Clinical Vignette 2 Clara is 42 year old 12 months previously recurrence of breast cancer with 4 bone metastases Treated with chemotherapy No comorbidities Bisphosphonate I.V.
25 Clinical Vignette 2 3 weeks previously Apparition bone pain (6-7/10) multiple sites Bone scan confirmed now wide spread bone metastases Prescription: NSAID Hydromorphone 2 mg PO q 4hrs and BTA 2 mg q 1 hr PRN
26 Clinical Vignette 2 2 weeks previously: Her Pain 6/10 despite 4-5 BTA per day Increase Oral HM to 4 mg q 4 hrs and 3 mg q 1 hr PRN
27 Clinical Vignette 2 1 weeks previously: Her Pain 7/10 despite 3-4 BTA per day Increase Oral HM to 6 mg q 4 hrs and 3 mg q 1 hr PRN
28 Clinical Vignette 2 Today Pain 6/10; somnolence + Hydromorphone 6 mg PO q 4 hrs with BTA 4 mg (5-6/day) (36+20=46 mg/day) Mild constipation No other complains
29 Question Why is the pain not responding to opioid treatment? 1. Opioid neurotoxicity 2. Opioid tolerance 3. Specific type of opioid low responsiveness 4. Opioid Hyperalgesia 5. Progression of disease
30 Question Why is the pain not responding to opioid treatment? 1. Opioid neurotoxicity (A) 2. Opioid tolerance 3. Specific type of opioid low responsiveness 4. Opioid Hyperalgesia 5. Progression of disease
31 Poor response to one opioid/uncontrolled pain % of Response 80 % Oxycodone Morphine Important side effects Dosage June 24th, 2012
32 Rotating to oxycodone What is the conversion ratio of oxycodone to hydromorphone? : : : :1
33 Rotating to oxycodone What is the conversion ratio of oxycodone to hydromorphone? : : : :1
34 How do we proceed? Hydromorphone 46 mg orally/day Morphine 230 mg orally/day Oxycodone 154 mg orally/day (M/0: 1.5 (2)/1; 230/1.5=154) Oxycodone 20 mg ( 20%) orally q 4 hrs and 12 mg q 1 hr PRN Pitfall: Risk of undertreatment
35 Clinical Vignette 3 Asked to see Robert on the oncology floor 72 years old Found to have a metastatic pancreatic cancer Tumor resistant to chemotherapy Previously had a well controlled pain Now: Epigastric pain 7/10, knife like Fentanyl patch 100 mcg/hr q 3 days
36 Clinical Vignette 3 Cachectic Confused with mild agitation Hallucinations Myoclonus +++ Dehydrated Chest X-Ray normal Urine culture positive High WBC and creatinine
37 Question Why is the pain not responding anymore to opioid treatment? 1. Opioid neurotoxicity 2. Opioid tolerance 3. Hyperalgesia 4. Progression of disease 5. Delirium
38 Question Why is the pain not responding anymore to opioid treatment? 1. Opioid neurotoxicity 2. Opioid tolerance 3. Hyperalgesia 4. Progression of disease 5. Delirium
39 Delirium: Rotation from Fentanyl Fentanyl % of Response Morphine Delirium threshold Dosage 39 June 24th, 2012
40 Clinical Vignette 3 Complex situation Rotation to morphine s/c Fentanyl to morphine: 25 mcg/hr = 25 mg (25-50) morphine s/c daily Fentanyl 100 mcg/hr = morphine 100 mg ( ) s/c daily by at least 50% ( mg s/c) Patient is cachectic (absorption?) further decrease, how much? Fentanyl remains available 12 hrs (fat reserve?)
41 Personnal approach by % the lower equivalent ratio (morphine 100 mg) Start Morphine 8 mg s/c q 4hrs (48 mg/day) 12 hrs after removal of Fentanyl patch Immediately allow Morphine 5 mg s/c q 1 hr for BTA Treat delirium (symptoms+infection+hydration)? Pitfall: dose still too high; multiple rotations Rotating to fentanyl: keep original opioid for 12 hrs; more chalenging
42 Rotation to Methadone Indications Failure of multiple rotations High doses of opioids Neuropathic pain Hyperalgesia Severe renal failure
43 Morphine/Methadone R = 0,11 p=0,5 Previous dose of morphine not predictive of final methadone dose Bruera E, et al. Pal Med, 2002.
44 Switching to Methadone Age Daily Dose of Methadone Day 0 Day 1 α Day 2 α Day 3 α Day 4 α MEDD* 2/3** 1/3** 0/3** Final Dose < 65 > 60 and 200 mg 3 mg TID 9-15 mg 65 > 60 and 200 mg 2 mg TID 6-15 mg All# > 200 and 600 mg 5 mg TID mg rarely > 45 mg * Morphine Equivalent Daily Dose ** = of initial MEDD # Get help
45 Take home tips Indications of switching opioids Poor pain control ( 20%) Hyperalgesia ( 20-40%) Delirium ( 50%) Rotation form and to Fentanyl patch more complex Rotation to Methadone Expertise needed Expert s support Could be quite beneficial
46 Enjoy Quebec City!!!
47 Opioid switching in cancer pain: From the beginning to nowadays; Sebastiano Mercadante, Eduardo Bruera, Critical Reviews in Oncology/Hematology 99 (2016)
Opioid Pearls and Acute Pain Management
Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program
More informationFighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationPALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST
PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted
More information1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective
Cancer Related Pain: Case-Based Pharmacology Jeannine M. Brant, PhD, APRN, AOCN Oncology Clinical Nurse Specialist Nurse Scientist Billings Clinic Conflicts of Interest Jeannine Brant has served on the
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationOpioid Use in Serious Illness
Opioid Use in Serious Illness Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado
More informationPain. November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine
Pain November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine Objectives To be able to define pain To be able to evaluate pain To be able to classify types of pain To learn appropriate
More informationPain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD
Pain management Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD Case #1 61 yo man with history of Stage 3 colon cancer, s/p resection and adjuvant chemotherapy with FOLFOX
More informationDelirium in Palliative Care. Case Studies 2015
Delirium in Palliative Care Case Studies 2015 Case 1 - Alex 35 yo M with metastatic melanoma Decreased LOC, unilateral hearing loss and bilateral vision loss, back pain, lower extremity weakness,? confusion/hallucinations
More informationAcute pain management in opioid tolerant patients. Muhammad Laklouk
Acute pain management in opioid tolerant patients Muhammad Laklouk General principles An adequate review and assessment Provision of effective analgesia (including attenuation of tolerance and hyperalgesia)
More informationMethadone: Essential Hospice Analgesic or Too Risky for Prime Time?
Methadone Background Methadone: Essential Hospice Analgesic or Too Risky for Prime Time? Developed originally as an antispasmodic and later used as an analgesic, starting in late 1940 s Used extensively
More informationOPIOID- INDUCED NEUROTOXICITY*
OPIOID- INDUCED NEUROTOXICITY* Sriram Yennu MD, MS, FAAHPM Palliative Care, Rehabilitation and Integrative Medicine U.T. M.D. Anderson Cancer Center *Slide Deck courtesy Dept PRIM MDACC PATIENT #1: MRS
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 22 AUGUST 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients Sebastiano Mercadante, Patrizia
More informationOpioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1
Opioid Case Studies Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN September 29, 2016 2015 MFMER slide-1 Disclosures Relevant Financial Relationship(s) None Off Label and/or
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More information4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t
Management of Acute Pain Crises Maggie O Connor, M.D. Retired Palliative Care Physician Hope is not the conviction that something will turn out well, but the certainty that something makes sense, regardless
More informationLumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.
Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical
More informationApproach to Acute Pain Management
Approach to Acute Pain Management Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Director, Palliative Care Service Associate Director, Colorado
More informationWhat s New 2003? What new treatments? What have you discontinued? More information please!
What s New 2003? What new treatments? What have you discontinued? More information please! 1 What s New 2003? Submissions = 137 UK = 52 (38%) Doctors = 60% Nurses = 25% Pharmacists = 15% 2 What s New?
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with
More informationEquianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine
Equianalgesic Dosing: Making Opioid Interchange Easier Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine 1 Why Change Opioids? Side Effects Insufficient Pain
More informationSwitching from Methadone to a Different Opioid: What Is the Equianalgesic Dose Ratio?
JOURNAL OF PALLIATIVE MEDICINE Volume 11, Number 8, 2008 Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2007.0285 Switching from Methadone to a Different Opioid: What Is the Equianalgesic Dose Ratio? Paul W.
More informationManaging Pain: A Focus on the Appropriate Use of Methadone
Managing Pain: A Focus on the Appropriate Use of Methadone Karla Anderson, PharmD Regional Client Liaison Anthony Contreras, RPh Regional Sales Associate Hospice Pharmacia, a division of excellerx, Inc.
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationOpioid Conversion Guidelines
Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,
More informationANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017
METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017 Ky Stoltzfus, MD Assistant Professor, Internal Medicine University of Kansas Medical Center ANSWER # 1 Your response might be
More information10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
More informationManaging Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder
Managing Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder Presented by: Kathleen Broglio, DNP, ANP-BC, ACHPN, CPE, FPCN on December 1, 2016 Webcast Questions and Answers (Answers
More informationObjectives. Patient Controlled Analgesia (PCA) Management in the Seriously Ill. Discuss principles for opioid dosing and titration for acute pain
Patient Controlled Analgesia (PCA) Management in the Seriously Ill Jeanie Youngwerth, MD University of Colorado School of Medicine Associate Professor of Medicine, Hospitalist Associate Director, Colorado
More informationCognitive Effects of Opioid Therapy. Cognitive Function. Prevalence. Delirium (DSM IV) Significance of Cognitive Effects
Cognitive Effects of Opioid Therapy Jeannine M. Brant RN, MS, AOCN St.Vincent Healthcare Billings, MT Cognitive Function! Brain s acquisition! Information system Processing Storage Retrieval! Includes:
More informationPractical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
More informationBASICS OF OPIOID PRESCRIBING 10:30-11:45AM
PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA BASICS OF OPIOID PRESCRIBING 10:30-11:45AM ACPE UAN: 107-000-14-013-L01-P Activity Type: Application-Based 0.125 CEU/1.25hr Learning Objectives for Pharmacists:
More informationIntractable pain syndrome is defined as persistent pain despite all the reasonable efforts to treat.
Difficult Pain Syndrome/Intractable/Refractory Pain Intractable pain syndrome is defined as persistent pain despite all the reasonable efforts to treat. Reasonable efforts Differs for specialties/regions/countries
More informationNarcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia.
Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia. Created: Monday, March 12. Online calculator to convert equianalgesic
More informationPain Management Strategies Webinar/Teleconference
Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits
More informationUniversal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?
Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities
More informationDisclosures. Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals
Anne F. Walsh, MSN, ANP BC, ACHPN, CWOCN Kathleen Broglio, MN, ANP BC, ACHPN, CPE Disclosures Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals
More informationPain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan
Pain management in palliative care Dr. Stepanie Lippett and Sister Karen Davies-Linihan contents Concept of total pain Steps in pain management Recognising neuropathic pain WHO analgesic ladder Common
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationPAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC
PAIN MANAGEMENT PGY-1 Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC Perception Matters A builder aged 29 came to the accident and emergency
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationPalliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015
Palliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015 Objectives Define palliative care and primary palliative care Describe the rationale for providing primary palliative care in
More informationPain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine
Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces
More informationPain Management in Hospice and Palliative Care
Pain Management in Hospice and Palliative Care A Case-based Approach JoAnne Nowak, M.D. Merrimack Valley Hospice Revised November 2011 Objectives Use a case study approach to stimulate discussion and illustrate
More informationSymptom Management Pocket Guides: DELIRIUM
Symptom Management Pocket Guides: DELIRIUM August 2010 DELIRIUM Page Considerations. 1 Assessment 2 Diagnosis. 3 Non-Pharmacological treatment 3 Pharmacological treatment. 5 Mild Delirium... 6 Moderate
More informationE-Learning Module N: Pharmacological Review
E-Learning Module N: Pharmacological Review This Module requires the learner to have read Chapter 13 of the Fundamentals Program Guide and the other required readings associated with the topic. Revised:
More informationRELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM
PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM ACPE UAN: 107-000-14-016-L05-P Activity Type: Application-Based 0.1 CEU/1.0 hr Learning Objectives for
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationCLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES
CLINICAL GUIDELINES F END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES OPENING STATEMENT: Insert Facility Name is committed to providing effective end-of-life symptom management to all residents. Symptom
More informationDemystifying Opioid Conversion Calculations
Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationReview of Pain Management with Clinical and Regulatory Updates
Review of Pain Management with Clinical and Regulatory Updates Palliative Care Collaborative: 8 th Annual Regional Conference October 10, 2014 Michael Stellini, M.D.,M.S. Medical Director, Hospice and
More informationDose equivalent of fentanyl patch to oxycontin
Dose equivalent of fentanyl patch to oxycontin 10-3-2018 Detailed dosage guidelines and administration information for OxyContin (oxycodone hydrochloride). Includes dose adjustments, warnings and precautions.
More informationManagement of Cancer Pain
Management of Cancer Pain Mihir M. Kamdar, MD Associate Director, Palliative Care Director, MGH Cancer Pain Clinic Depts of Anesthesia Pain/Palliative Care Massachusetts General Hospital None Disclosures
More informationChronic Pain Pharmacist role in the clinic
Chronic Pain Pharmacist role in the clinic WSPA Annual Meeting 2015 Alvin Goo, PharmD Clinical Associate Professor University of Washington Schools of Pharmacy and Family Medicine Speakers Declaration
More informationArresting Pain without Getting Arrested
G. Jay Westbrook, M.S., R.N., CHPN - Clinical Director Compassionate Journey: An End-of-Life Clinical & Education Service CompassionateJourney@hotmail.com 818/773-3700 Arresting Pain without Getting Arrested
More informationEvidence-based Best Practice in Pain Management
Foundations in Palliative Medicine Colorado, November 2017 Evidence-based Best Practice in Pain Management Sudy Jahangiri, MD Crystal Owens, MD Continuing Education Disclosures Approval Statement: The
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationOpioid Pain Management. John Manfredonia, DO. Disclosures. Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare
Opioid Pain Management John Manfredonia, DO Disclosures Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare VistaCare has provided commercial support for this activity Palliative
More informationPain Management Dilemmas. Five Pain Dilemmas. Barriers: Meet Loretta. Daniel Johnson, MD, FAAHPM
Pain Management Dilemmas Daniel Johnson, MD, FAAHPM Kaiser Permanente University of Colorado Five Pain Dilemmas 1. Barriers to Pain Management 2. Selecting and Titrating Opioids 3. Managing PCAs 4. Using
More informationPain and the MGH Promise
Pain is an unpleasant sensory & emotional experience associated with actual or potential tissue damage or described in terms of such damage Our promise to patients we will always: Work as a team to evaluate,
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program North Sydney April 12, 2018 This speaker has been asked to disclose to the audience any involvement with
More informationTHE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT
1 THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT Jaegtvolden 4-5 June 2012 14. 12. 2012 2 1 3 WHO ANALGESIC LADDER (1996) NSAID +/- Adjuvant STEP II OPIODS Opids for mild to moderate
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationTo Infinity and Beyond! Safe and Effective Opioid Titration Strategies
To Infinity and Beyond! Safe and Effective Opioid Titration Strategies Alexandra L. McPherson, PharmD, MPH Slide development Mary Lynn McPherson, PharmD, MA, BCPS, CPE Professor and Executive Director,
More informationPain Management: principles and practice
Pain Management: principles and practice Dr. G.A.Spry Beach Club Resort 7 th March 2015 Objectives Assess pain as a symptom Principles of opioid prescribing Opioid dose conversions Common opioid side effects
More informationMitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly
Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mary Lynn McPherson, PharmD, MDE, MA, BCPS, CPE Professor and Executive Director, Advanced Post-Graduate
More informationPain Management in Medical Dermatology
Pain Management in Medical Dermatology Robert G. Micheletti, MD Assistant Professor of Dermatology and Medicine Director, Cutaneous Vasculitis Clinic, Penn Vasculitis Center Co-Director, Inpatient Dermatology
More informationOpioid Conversions Mixture of Science and Art
Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu
More informationPain Management in Medical Dermatology
Pain Management in Medical Dermatology Robert G. Micheletti, MD Assistant Professor of Dermatology and Medicine Director, Cutaneous Vasculitis Clinic, Penn Vasculitis Center Co-Director, Inpatient Dermatology
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationUpdate on Pain: Collaborative Care for the Complex Patient
Update on Pain: Collaborative Care for the Complex Patient Nirmala R. Abraham, MD Medical Director Sycamore Pain Management Center Kettering Health Network Objectives Standardized approach to patient care
More informationSharon A Stephen, PhD, ARNP, ACHPN. September 23, 2014
Sharon A Stephen, PhD, ARNP, ACHPN September 23, 2014 Case-based presentation selected to discuss: Pain assessment Barriers to adequate pain relief Pharmacologic interventions Non-Pharmacologic interventions
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationTapering Opioids Best Practices*
Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand
More informationPain: What You Need to Know to Advocate
Pain: What You Need to Know to Advocate Amy M. Corcoran, MD Assistant Professor of Clinical Medicine Department of Medicine, Division of Geriatrics University of Pennsylvania Associate Medical Director
More informationWhat to do when you are called to see a patient with... PAIN. Susan Merel, MD Division of General Internal Medicine July 2018
What to do when you are called to see a patient with... PAIN Susan Merel, MD Division of General Internal Medicine July 2018 Disclosures Susan Merel has no relationships with any entity producing, marketing,
More informationOpioids in Serious Medical Illness
Opioids in Serious Medical Illness Jacob J. Strand, M.D. Assistant Professor of Medicine Medical Director, Palliative Care Clinical Services Mayo Clinic Mayo Clinic Opioid Conference 2013 MFMER slide-1
More informationOpioids and adjuvant analgesics in palliative care
Opioids and adjuvant analgesics in palliative care Amy Allen Case MD, FAAHPM Supportive Care Department Chair, Palliative Care Program Chief Roswell Park Cancer Institute Associate Professor of Medicine
More informationCancer Pain: A Clinical Overview. Linda A. King, MD Section of Palliative Care and Medical Ethics
Cancer Pain: A Clinical Overview Linda A. King, MD Section of Palliative Care and Medical Ethics Objectives Define Palliative Care Review prevalence of cancer pain Know barriers to cancer pain management
More informationEnd-of-Life Pain Management: How to do it right Wayne Kohan MD Medical Director Chaplaincy Hospice Care
End-of-Life Pain Management: How to do it right Wayne Kohan MD Medical Director Chaplaincy Hospice Care Objectives Discuss the rational use of opioid medications, including dosing and dose titration, routes
More informationSymptom Control in the Community Setting. Dr Andrew Tysoe-Calnon
Symptom Control in the Community Setting Dr Andrew Tysoe-Calnon Lead Consultant t Common symptoms Pain Agitation Shortness of breath Nausea and vomiting Intestinal obstruction Confusion Pain Occurs in
More informationCancer Pain Management: An Overview
Cancer Pain Management: An Overview Dr. Mike Harlos Medical Director, WRHA Palliative Care 1 Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described
More information16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces
16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces Moderators: Kendra Grim, MD, Robert T. Wilder, MD, PhD Institution:
More informationPo dilaudid versus iv dilaudid
Po dilaudid versus iv dilaudid Search IM/IV/SC 120 mg ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic an equianalgesic ratio for PO. Dilaudid official prescribing
More informationAppendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline
Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline 1. Pharmacist to order Narcotic Withdrawal Scores QH X 4 hours, then per table below: Narcotic Withdrawal Score
More informationANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT
ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More information2-ethylidene-1,5-dimethyl-3,3diphenylpyrrolidene (EDDP) Safe in stable liver disease Long acting
2012 AAHPM & HPNA Annual Assembly March 7-10, 2012 Denver, CO Methadone the Taming of the Shrew Stefan J. Friedrichsdorf, M.D. Medical Director Department of Pain Medicine, Palliative Care & Integrative
More informationAcute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX
Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated
More information1
Disclosures I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More information